Merck & Co., Inc. $MRK Stock Holdings Lowered by Courier Capital LLC

Courier Capital LLC cut its stake in Merck & Co., Inc. (NYSE:MRK) by 89.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,398 shares of the company’s stock after selling 48,205 shares during the period. Courier Capital LLC’s holdings in Merck & Co., Inc. were worth $784,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Horizons Wealth Management bought a new position in Merck & Co., Inc. in the 3rd quarter worth about $30,000. Bullseye Investment Management LLC purchased a new position in shares of Merck & Co., Inc. during the second quarter worth approximately $27,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Graney & King LLC raised its stake in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after acquiring an additional 200 shares in the last quarter. Finally, Montgomery Financial Services LLC purchased a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth $41,000. Institutional investors own 76.07% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David Williams sold 52,847 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Maraldo sold 18,706 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of recent research reports. Guggenheim increased their price objective on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Jefferies Financial Group lifted their price target on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. TD Cowen upped their price target on Merck & Co., Inc. from $137.00 to $155.00 and gave the stock a “hold” rating in a research report on Wednesday, September 23rd. Berenberg Bank upped their price target on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a research report on Friday, September 11th. Finally, Royal Bank Of Canada decreased their price target on Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a research note on Monday. Seventeen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Oncology pipeline update: Merck will present first-time results from three pivotal Phase 3 trials, along with more than 90 additional abstracts covering over 20 tumor types, at the ESMO 2026 Congress on October 23–27. The event could provide important evidence of Merck’s ability to replenish growth as investors look beyond its existing portfolio. Merck ESMO 2026 oncology pipeline update
• Positive Sentiment: Upcoming earnings catalyst: Merck is expected to report third-quarter results in roughly two weeks, with analysts forecasting single-digit EPS growth. The report may clarify operating trends, full-year guidance and the effect of recent pipeline developments. Merck next earnings report expectations
• Neutral Sentiment: Board addition: Merck elected Paul J. Diaz, a healthcare executive, to its board of directors. The appointment may strengthen the board’s operating and healthcare expertise, but no immediate financial impact was announced. Paul J. Diaz elected to Merck board
• Neutral Sentiment: Analyst price targets remain mixed: Citi raised its target to $145 while retaining a neutral rating, whereas RBC lowered its target to $145 and maintained a sector-perform rating. These changes suggest limited near-term conviction despite the stock’s strong six-month performance.
• Negative Sentiment: Remigromig concerns: Jefferies cut its peak sales forecast for Merck’s experimental diabetic macular edema treatment by 60%. Although the Phase 2b/3 study met its non-inferiority goal against Lucentis, the drug showed smaller numerical vision improvements and raised efficacy and safety concerns, reducing its perceived commercial opportunity. Jefferies cuts remigromig sales forecast
• Negative Sentiment: Lower earnings estimates: Erste Group reduced its FY2026 EPS estimate to $2.73 from $2.75 and its FY2027 estimate to $9.47 from $9.52. The modest cuts reinforce pressure on expectations, even though broader estimates remain higher than the current-year consensus cited in the reports.

Merck & Co., Inc. Stock Performance

MRK traded down $3.48 on Tuesday, reaching $141.97. The stock had a trading volume of 8,377,313 shares, compared to its average volume of 10,630,645. The business’s 50-day moving average price is $144.25 and its two-hundred day moving average price is $128.57. The company has a market cap of $350.27 billion, a P/E ratio of 113.58, a price-to-earnings-growth ratio of 6.58 and a beta of 0.21. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. Merck & Co., Inc.’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. Merck & Co., Inc.’s payout ratio is 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.